文献速递中医内科中药与中成药合理使用

冬虫夏草双向调节心律失常:临床评价与网络药理学

Bidirectional regulatory effects of Cordyceps on arrhythmia: Clinical evaluations and network pharmacology.
PubMed 文献 · Front Pharmacol · 2022-08-19

冬虫夏草显著提高心动过缓(RR=1.24;95%CI 1.15-1.35;Pz<0.00001)和心动过速(RR=1.27;95%CI 1.17-1.39;Pz<0.00001)的总有效率,未发生严重不良事件;网络药理学提示机制可能与心肌细胞肾上腺素能信号及PI3K-Akt通路相关。

要点

  • 冬虫夏草联合常规药物可提高心动过缓及心动过速的总有效率。
  • 治疗中未见严重不良事件,安全性较好。
  • 潜在靶点包括IL6、TNF、TP53、CASP3、CTNNB1、EGF和NOS3。

核心结论

  • 冬虫夏草对心律失常治疗有一定正向作用,主要机制可能通过调节心肌细胞肾上腺素能信号和PI3K-Akt通路。

主要发现

  • 心动过缓总有效率RR=1.24(95%CI 1.15-1.35,Pz<0.00001)。
  • 心动过速总有效率RR=1.27(95%CI 1.17-1.39,Pz<0.00001)。
  • 冬虫夏草组次要结局也有获益,且无严重不良事件。
  • KEGG富集主要涉及心肌细胞肾上腺素能信号和PI3K-Akt信号通路。
  • IL6、TNF、TP53、CASP3、CTNNB1、EGF和NOS3可能是关键靶点。

关键数值与推荐

  • 6项试验报告心动过缓,13项报告心动过速。
  • 二分类变量用RR及95%CI,连续变量用SMD及95%CI。
  • 网络药理学用Metascape进行GO和KEGG通路富集分析。

临床怎么用

  • 冬虫夏草(如宁心宝胶囊)可考虑作为心动过缓或心动过速的辅助治疗,与常规药物联用。
  • 使用时应关注潜在靶点相关通路,但需结合患者具体心律失常类型个体化评估。

局限性

  • 原文未报告纳入试验的具体偏倚风险、异质性及发表偏倚评估结果。
  • 网络药理学结果仅为预测,缺乏实验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Cordyceps is a precious Chinese herbal medicine with rich bio-active ingredients and is used for regulating arrhythmia alongside routine treatments. However, the efficacy and potential mechanisms of Cordyceps on patients with arrhythmia remain unclear. Methods: Randomized controlled trials of bradycardia treatment with Cordyceps were retrieved from diverse databases and available data. Dichotomous variables were expressed as a risk ratio (RR) with a 95% confidence interval (CI). Continuous variables were expressed as a standardized mean difference (SMD) with a 95% CI. Network pharmacology was used to identify potential targets of Cordyceps for arrhythmia. Metascape was used for gene ontology (GO) and genome (KEGG) pathway enrichment analysis. Results: Nineteen trials included 1,805 patients with arrhythmia, of whom 918 were treated with Ningxinbao capsule plus routine drugs, and, as a control, 887 were treated with only routine drugs. Six trials reported on bradycardia and the other 13 on tachycardia. Treatment with Cordyceps significantly improved the total efficacy rate in both bradycardia (RR = 1.24; 95% CI, 1.15 to 1.35; Pz <0.00001) and tachycardia (RR = 1.27; 95% CI, 1.17 to 1.39; Pz <0.00001). Cordyceps also had beneficial secondary outcomes. No serious adverse events occurred in patients treated with Cordyceps. The results of KEGG pathway enrichment analysis were mainly connected to adrenergic signaling in cardiomyocytes and the PI3K-Akt signaling pathway. IL6, TNF, TP53, CASP3, CTNNB1, EGF, and NOS3 might be key targets for Cordyceps in the treatment of arrhythmia. Conclusion: This study confirmed that Cordyceps has a certain positive effect on the treatment of arrhythmia and that its main mechanism may be through the regulation of adrenergic signaling in cardiomyocytes and the PI3K-Akt signaling pathway.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wang L, Sun H, Yang M, et al. Bidirectional regulatory effects of Cordyceps on arrhythmia: Clinical evaluations and network pharmacology. Front Pharmacol. 2022. PMID: 36059969. doi:10.3389/fphar.2022.948173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。